AntriaBio

Investors

Press Releases

Apr 4, 2018 Rezolute Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors
Apr 3, 2018 Rezolute, Inc. Announces Close of Convertible Note Financing
Dec 26, 2017 UPDATE - Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC
Dec 7, 2017 AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.
Oct 17, 2017 AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema
Oct 9, 2017 AntriaBio Appoints Nektar Therapeutics CFO to its Board of Directors
Oct 4, 2017 AntriaBio Appoints Dr. Robert Bhisitkul to its Scientific Advisory Board
Aug 7, 2017 AntriaBio and ActiveSite Pharmaceuticals Announce License and Development Agreement for Plasma Kallikrein Inhibitors
Jul 25, 2017 AntriaBio Announces First Patient Dosed in Phase 1 Clinical Study of AB101
Jul 17, 2017 AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month

<< Previous
1
2
3
4
5
6
7
8
Next >>

Show All